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Treatment of Haemophilia A with purified Factor VIII obtained from
Human Plasma by Cryoprecipitation
K. Mrvnn, Dn. J. G. EnnNrssl, J. J. Vrlrravp, Dr. H. C. Ilnursn and Dn. E. A. Lonrrcsn
A few years ago it was discovered by coincidence
that so-called cryoprecipitate - a protein fraction
which precipitates from human plasma at a low
temperature under certain conditions - contains
an abundance of a clotting factor which is lacking
in haemophilia A, and which is known by inter-
national agreement as Factor VIII1z. In view of an
exceedingly encouraging report from the USA3
on the clinical validity of cryoprecipitate in the
treatment of haemophilia A, we started the pro-
duction of this fraction in December 1965. Our
purpose was to establish whether cryoprecipitate
would be suitable for the treatment of haemo-
philiacs, particularly in the case of an operation
or after severe injuries, in which instances the
conventional products (fraction I according to
ConN, fraction I-O according to BroueAcr,
animal fractions) had been only partly satis-
factoryro.
In order to evaluate cryoprecipitate, we deter-
mined both the yield and degree of purity in vitro,
and the activity of purifled Factor YIII in vivo,
with special reference to the relation between the
quantity administered and the resulting blood
concentrations.
Finally we attempted to establish whether
transfusion of cryoprecipitate exerts any influence
on the degree of physiological Factor VIII pro-
duction in patients with the mild type of haemo-
philia A (with a Factor VIII level of 5-25 pct).
Mnrnoos
Pro ce dure of cr y op r e cipit at e product ion72, 15
Some 5oo ml blood is collected under vacuum into
one of the two bags of a double-bag plastic system*.
Such a system consists of a main bag and a satellite
bag, interconnected by plastic tubing. The blood is
collected into the main bag, the collecting time being
generally less than 6 minutes. The bags are centrifuged
for 3o minutes at 4oC at 4ooo x g. A plasma extractor
is then used to transfer the plasma (current routine
production is about 28o grams per bag) to the satellite
bag. The latter is subsequently suspended for zo-3o
minutes in a COr-alcohol mixture at -6o'to -3o'C.
The two bags, still connected, are then placed in a
refrigerator at 4"C. After zo-24 hours the slowly
thawing plasma contains a floccular precipitate: the
so-called cryoprecipitate.
The bags are then centrifuged for zo minutes at 4'C
at 3ooo x g, in the course of which the precipitate at-
taches itself to the bottom and lateral walls of the
satellite bag. The plasma is allowed to flow back into
the erythrocyte concentrate in the main bag, while the
cryoprecipitate remains in the satellite bag. The bags
are then clamped off and separated. Satellite bags
with the cryoprecipitate are stored at low temperature,
originally at -25'C, currently at -7o"C.
To prepare the cryoprecipitate for transfusion pur-
poses, the required number of bags are taken from the
deep freezer and placed for one minute in a water
bath at 37"C to soften the plastic. The bags are opened
by severing the (iodinized) tubing with sterile scissors,
whereupon a syringe is used to .add about 5 ml of a
sterile buffer solution (r part o.ro9 M sodium citrate
and 5 parts o.9 pct NaCl solution) to each bag. To
ensure rapid solution of the cryoprecipitate, the tubing
is clamped off with a Kocher clamp and the bags are
placed for a few minutes in a water bath at 37'C. The
contents are then poured into a sterile siliconized
bottle and the bags are rinsed out at least twice with
the same amount of citrated salt solution. The ultimate
volumes of ro bags total r 5o-zoo m1, a few ml of which
is used for bacteriological examination and determina-
tion of Factor VIII activitv.
*Initially we used Fenwal double blood-pack units J-D2, but later on those supplied by the Blood Trans-
fusion Service of the Netherlands Red Cross, Amsterdam which contain 75 ml of anhydrous di-sodium
citrate 2.7 pct and anhydrous dextrose 2.3 pct.
From the Haematology Section of the Department of Internal Medicine, University Hospital, Leiden
Manuscript received March r967.
Folia Med. Neerl., to ( r967)
50 lreatment of haemophilia A with Factor VIII obtained by cryoprecipitation
Factor VIII assay
Equipment: Coagulometer for automatic recording of
coagulation times according to ScHNrrcERrT (Depex,
de Bilt, Netherlands); facilities for centrifugation at
4'C and 2o.ooo x g; glassware and plastics: sili-
conized blood bank bottles (5oo and 35o ml); parafilm
"M" @iv. of Am.Can.Comp., Wisconsin, USA);
calibrated pipettes; ordinary glass, disposable, round
bottomtubes (9.5-r r.7 x 55 mm) foruse inthe coagulo-
meter (Depex, de Bi1t, Netherlands); ordinary glass,
siliconized, round bottom tubes (16-17.5 x Ioo mm)
used for preparing dilutions; polystyrol crystal, flat
bottom tubes (r5-r7x56 mm) with polythene cap,
for collecting blood and storing plasma samples
(Emnosa, Zuun, Belgium).
Reagents: Veronal buffer pH 7.4, o.o5 M, according
to MrcnaErrs; Calcium chloride o.o33 M; Light
kaolin (British Drug Houses, Poole, Great Britain);
Phospholipid according to BELL and AlroNl, stored
in small amounts at -25"C; Sodium citrate o.55 M
(about 20 pct solution).
Normal pooled plasma.' From each of 4 normal
individuals known to display a mean Factor VIII
activity of about roo pct, roo ml blood was collected
on 2 ml sodium citrate o.55 M, and thoroughly mixed
before centrifugation for 3o minutes at I25o x g. The
supernatant plasma was pooled, centrifugated at
2o.ooo x g for 3o minutes at 4"C and stored in r ml
portions at -7o"C. This procedure takes about two
hours.
Test plasma: Blood was collected in a polystyrol tube
containing o.55 M sodium citrate (o.r ml for 4.9 ml
blood). After thorough mixing the blood was centri-
fugated aI r21o x g for 15 minutes. Platelets were
almost completely removed from the supernatant
plasma by centrifugation for 3o minutes at 4"C at
2O.OOO x g.
Reagent plasma.' From a patient with a severe type
of haemophilia A (< t pct Factor VIII), blood was
collected in a siliconized blood bank bottle (6o ml
ACD for 44o ml blood), gently mixed during collection
and dEntrifuged for one hour at 4oC at I8oo rpm. The
supernatant plasma, practically freed from platelets
by centrifugation for 3o minutes at 2o.ooo X 9., was
stored in small amounts at -25"C.
Procedure: A modification of the one-stage method
as described by H.lnorsrv and McPnERsoNa was
adapted for use in the coagulometer: a series of test
tubes are fllled successively with o.r ml offreshly thawn
reagent plasma, o.r ml of a dilution of normal or test
plasma, and o.r ml of a kaolin suspension (5 mg/ml
phospholipid solution). The contents are thoroughly
stirred and the tubes are then placed in the thermostat
housing of the coagulometer. Maximum contact
activation is achieved after an incubation period of
3o minuteszO. The reaction is then started by admixing
o. r ml pre-heated CaCl, o.o33 M, and the coagulation
times are recorded by the coagulometer. All deter-
minations are made in triplicate, the second and third
series (Fig. r) being prepared during the incubation
period of the first. The Factor VIII activity in the test
plasma is then read from the standard curve obtained
by plotting the logarithm of the calculated Factor
VIII content in dilutions of normal plasma against
the logarithm of the clotting times observed with these
dilutions. Dilutions of the normal reference plasma
are always chosen so as to give a range of clotting
times that includes the clotting times found with the
test sample, in order to avoid extrapolation of the
standard curve. Statistical analysis of over roo deter-
minations 5' 20 failed to demonstrate any difference
between the standard curve in the range used, and a
straight line. The experimental error of this method is
between 5 pct and 8 pct.
Fibrinogen determination
A quantitative immuno-precipitation technique was
usede, 16.
Protein determination
According to KrBro.lur.
Fig. r. Principle of Factor VIII-assay with the use of ScnNrrcrn's coagulometer. The three series serve for
triplicate determination of the samples to be tested (for further explanation see text).
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Taern I: CI-rNrcx. DATA oF 9 llnelr4opHrlre A parrrNrs TRANSFUSED wrrH coNcENTRATED Facrpn VIII
\
5r
Patients Age
( years)
Factor VIII Reason for
level (pct) admission
Blood vol. Haematocrit Plasma vol. Body temp.**(l) (pcr) (l) (c")
P. J. J.
P. K.
G . v . W
J. C. O.
H. P. R.
H. v. M.
A. P.
52
36
32
42
J )
1 8
46
20
1 7
< l
< l
< 1
I*
II
I
II
I
II
I
II
I
il
T
il
I
II
III
IV
v
VI
I
II
III
IV
I
II
< l
< 1
< 1
6.0
8.9
14.8
I  1 .1
14.0
10.0
6.0
1,2.5
6.4
6.8
3.4
3.5
3.78
5.23
4.01
5.O7
4.88
4.01
5.65
36
40
38
39
46
46
44
4)
35
38
J J
J J
34
J J
21,
J J
31
30
43
45
44
45
A 1
A '
2.56
, 4 )
3.44
3.39
2.35
2.3s
3.06
3 .15
3.34
3.21
2.82
2.82
3.92
3.97
4.58
3.97
4.07
4.12
3.71
3.60
3.65
3.60
3 .12
3 .12
t t . t
37.6
37.0
37.5
37.5
37.2
37.1
37.5
3 7 . 1
) t . 3
37.4
37.2
37.1
37.O
37.2
37.1
37.3
37.0
38.2
37.5
37.2
t t . +
37.9
38.1
muscular
haematoma
haematuria
tooth
extraction
haemarthros
haemarthros
haematuria
haematuria
J. L.
B. J. B.
tooth
extraction
tooth
extraction
6.05
5.01
*Roman numerals refer te the number of transfusion experiments.
**Maximum rectal temperature registered during the day of the transfusion: all the other data relate to the
situation prior to transfusion.
Parrnurs
Cryoprecipitate was tried out in ro patients suffering
from haemophilia A. Nine of them were adult volun-
teers; the tenth was a 6-year-old boy who, after con-
sultation with the parents, was subjected to a hernio-
tomy under cryoprecipitate protection.
Six of the 9 adults suffered from a severe type of
haemophilia A (< I pct Factor VIII), while the other
3 showed the mild type of haemophilia A (Factor
VIII 5-25 pct). An indication for treatment existed in
all cases. Five of the 6 patients with a severe type of
haemophilia A were clearly "polytransfusees", whose
risk of transfusion hepatitis could be regarded as
minimal.
Table I presents data on the nine adult haemophi-
liacs, including data on the blood volume as deter-
mined with the aid of Ct'1-labelled erythrocytes (the
plasma volume in these patients was calculated from
blood volume and haematocrit value; the body's
haematocrit value was estimated ro pct lower than the
value obtained for peripheral blood).
The surgical patient F. v. L. was the second son of
a known carrier of mild type haemophilia. In his case
Factor VIII activity before the operation was about
ro pct of normal; his body weight was 22 kg, and on
the basis of this weight the plasma volume was esti-
mated at o.88 L The operative indication was a right-
sided inguinal hernia which had become incarcerated
several times.
Rnsurrs
Properties of cryoprecipitate in vitro
Factor I/III yield; Concentration of fibrinogen and
other proteins.' From the yield of z8 samples,
each derived from ro pooled cryoprecipitates, it
was calculated that the yield per cryoprecipitate
averages 44.8 pcI of the Factor VIII activity, 4r.r
pct of the fibrinogen concentration and r.4 pct of
the concentration of other proteins present in the
original plasma. Assuming that the amount of
Folia Med. Neerl., ro ( 1967)
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Tnnr,n II: RncovxRy rN vrvo or Flcron VIII rn.q.Nsrusno As A CRYoPREcIPTTATE
Mean plasma
volume( t)
Number of
transfusions 
1
Mean amount and range
of Factor VIII*
transfused recovered
Average
/ecovery
(pct)
Severe-type
haemophilia
(6 patients)
Mild-type
haemophilia
(3 patients)
2.91
3.79
10312
12
901 929
(504-1620) (623-1186)
917 854
(s47-r254) (659-1154)
*Expressed as equivalents of freshly drawn net normal plasma in ml'
original plasma per cryoprecipirate averages 244
ml ACD plasma (:zSo g), i.e. r94 ml net plasma,
this means that - in terms of Factor VIII, fibri-
nogen and other protein concentrations - one
cryoprecipitate corresponds with 87, 8o and 2.6
ml fresh plasma, respectively. The average total
protein concentration per cryoprecipitate is ap-
proximately that of 7 ml fresh net plasma. The
coemcient of variation of the Factor VIII activity
found per ro pooled bags was calculated to be
16 pct. Given an error of determination of 7 pct,
this means that the coemcient of variation for the
yield per ro pooled bags amounts to some 14 pct
Q/ 156-49 pct) and for the yield per bag to
about 45 pct (r4 pct x y'ro). The Factor VIII
yield per donor, therefore, varies widely.
Iso-antibody concentration : ltt two random sam-
ples of ro pooled cryoprecipitates (zoo and r8o ml,
respectively), obtained from donors with blood
group O, determinations disclosed titres of 1/tu
and l/ru, respectively, for complete antibody anti-
A, and 1/s and 1/a, respectively, for anti-B; incom-
plete antibodies and haemolysins were not de-
monstrable.
Activity of purified Factor VIII in vivo
Recovery: Each of the six adult patients with
severe haemophilia A received two infusions of
ro pooled cryoprecipitates, usually with an inter-
val of only a few days. The three patients with
mild haemophilia A likewise received repeated
infusions of ro pooled cryoprecipitates (the first
being given six, the second receiving four and the
Folia Med. Neerl., to ( 1967)
third receiving two infrrsions). The duration of
the infusion was r5-zo minutes in all cases.
Ten minutes after completion of the infusion a
separate venipuncture was performed to collect
blood for determination of the Factor VIII con-
centration attained. The recovery was calculated
by relating the vahre found lz vivo to the value,
predicted on the assumption of a homogeneous
distribution over the intravascular plasma volume
of the amount of cryoprecipitate administered.
The latter was obtained from determinations ln
vitro (Table II). Statistical analysis showed that
both in the group with severe and in that with
mild haemophilia" the average recovery is not
significantly difierent fro,m roo pct.
Distribution od degr&tion' In order to deter-
mine the rate of clearance of the transfused
Factor YIII from the blood, the Factor VIII
activity was meazured at regular intervals during
the first 3z hours after administration. Table III
presents a summary of the individual values
found. In none ofthe patients did an exceptional-
ly rapid clearance of Factor VIII suggest the
presence of an iso-immune antibody against
Factor YIII. Figures z and 3 show Factor VIII
clearance curves for the group with severe and
that with mild haemophilia A, respectively. The
curves are the optimal lines drawn through the
geometric means calculated for the two groups of
patients from the values indicated in Table III as
found at corresponding times. In calculating the
points for Figure 3 after infusions I and III in
patient J. L., only the first two values were used
treatment of haemophilia A with Factor VIII obtained by uyoprecipitation 53
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because the second follow-up was followed by a
tooth extraction under local anaesthesia with
procaine and adrenaline (about o.o4-o.o8 mg),
whereupon Factor VIII activity in both cases
showed a significant increase.
The clearance cwves presented in Figures z and
3 are both diphasic: Factor VIII activity showed
a higher rate of diminution during the first z4
hours than subsequently. On statistical grounds
the data obtained in patients with severe haemo-
philia A warrant the following assumptions:
r) the rate of clearance during the second phase
takes an exponential course with a biological
halflife of r4 hours, anil z) the first phase is
characterized by summation of the slow inactiva-
tionmentionedunder r) and a second, more rapid,
possibly also exponential clearane (probably the
result of equilibration between the intravascular
and the extravascular distribution space), the half-
life of which is estimated at 4 hours (see Fig. z).
Folia Med. Neerl., ro (1967)
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The curve in Figure 3 differs fromthat in Figure
z in two respects. Firstly, the maximum rise (ro-
minute value redueed by the mean pre-value of
2.8 pct) with z4 pct is obviously lower than that
found for the group of severe haemophiliacs.
Secondly, the slope of the second phase of the
clearance curve is definitely less steep. The former
difference is explained by the considerably larger
intravascular plasma volume in the three mild
haemophiliacs. The flatter clearance curve might
be explained by assuming that the physiol-
Folia Med. Neerl., ro (1967)
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2320
ogical Factor VIII production remains unchanged
during and after infusion. To verify the latter
hypothesis, the values found for severe haemo-
philiacs (F!g. z) were converted on the basis of
the mean plasma volume in the mild haemophi-
liacs (the plasma volume in the severe haemophi-
liacs:was't'ivo-thirds of that found in the mild
haemophiliacs), and increased by the mean pre-
value of 7.8 pct Factor VIII activity. The:esults
of this calculation are indicated by the circles in
Figure 3. At corresponding times, no statbtically
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convincing difference is observed between the
circles and the dots. Our hypothesis that the phy-
siological Factor VIII production does not
change during and after infusion of cryoprecipi-
tate therefore stands. /-
Haemostatic action:/In all cases which showed
definite haemorrhage prior to transfusion or in
which tooth extractions were performed, the
haemosfatic effect of cryoprecipitate was highly
satisfactory. The six-year-old boy who underwent
a herniotomy under cryoprecipitate protection
made an unev€ntful postoperative recovery. Fi-
gure 4 shows that the Factor VIII level was main-
tained at a very safe level throughout the post-
operative period of ro days.
Side effects: None of the patients showed any
side effects. The haematocrit value remained
virtually unchanged. As Figure 4 indicates, the
activity of the factors of the prothrombin com-
plex did not change, and the platelet count
showed no important variations during several
days of cryoprecipitate substitution therapy.
One patient did develop severe hepatitis with
hepatic coma 6 weeks after transfusion; this pa-
tient made a complete recovery after an exchange
transfusion2.
DlscussroN
As pointed out in the introduction, an American
report on the exceptional properties of a new
Tnnu III: Prasul LEvELs oF F.q.cron VIII lFrBn rRANsFUsroN oF cRyopREcrprrATE
Patients Time after transfusion
minutes hours
287o
Severe-t1pe haemophilia
P, J. J. I*
II
P . K .  I
II
G . v . W .  I
il
J . C . O ,  I
II
H . P . R .  I
II
H . v . M .  I
II
Mild-type haemophilia
A . P .  I
II
III
IV
V
VI
J . L ,  I
II
ilI
w
B . J . B .  I
II
29.O 27.0
39.0 38.0
25.8 19.6
31.0 22.5
26.5 22.0
37.0 27.0
31.0 30.0
26.0 23.5
35.5 29.0
30.0 2s.0
38.0 33.0
37.0 33.0
28.0 23.0
25.5 24.0
33.5 30.5
28.O 23.5
31.0 22.O
38.0 32.5
28.5 25.0
31.0 32.0
35.8 31.5
26.0 22.O
34.0 31.0
39.8 32.0
24.5 23.5
31.0 21.1
1.2.9 12.2
21.5 19.0
20.5 12.4
19.4 13.6
23.0 16.5
20.5 17.8
21.0 18.0
22.0 18.5
29.0 1s.7
26.0 17.1
18.7 16.7
22.5 21.5
27.O 24.0
23.5 20.0
23.5 24.0
26.5 25.0
43.0 26.7
20.o 18.6
37.5 20.3
zt .o l4 .s
26.0 18.0
21.5 16.0
9.4 9.5
15.5 13.8
4.9 4.7
4.6 6.7
4.8 2.2
4.6 3.8
8.2 7.8
7.5 6.6
9.s 7.8
6.5 6.8
8.7 '8.0
9.5 7.9
13.7 11.1
l7.o 16.7
23.0 19.4
21.0 16.3
20.0 16.6
20.3 16.5
23.0 13.0
10.4 to.1
11.3 10.0
9.8 7.6
7.5 7.4
8.0 5.2
7.2 7.1
12.2 9.1
2.6 2.8
4.1 4.4
2.7 1.9
2.6 2.4
4.4 3.3
5.5 4.0
7.2 6.3
< i  < t
4.7 4.1
4.1 3.5
12.6 11.5
11.8 10.0
18.0 18.0
15.6 11.8
15.3 12.5
13.6 11.0
8.7 10.3
9.9 9.3
10.0 7.r
7.9 6.8
6.0 4.6
4.8 4.0
*Roman numerals refer to the number of transfusion experiments.
For pretransfusion levels see Table I and for explanation of the figures in heavy print see text.
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Fig. 4. Data concerning treatment and clinical course of a patient suffering from haemophilia A operated
upon for an inguinal hemia. Arrow indicates operation.
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human Factor VIII product called cryoprecipi-
tate6'12,13,14,15 led to the above described prelimi-
nary study. The results warrant several conclu-
Folia Med. Neerl., to (t967)
sions, primarily with regard to the properties
of cryoprecipitate.
The Factor VIII activity in cryoprecipitate, as
treatment oJ'haemophilia A with Factor VIII obtained by cryoprecipitation 57
determined in vitro, amounts to almost 45 pct of
that in the original plasma. Ten pooled cryopre-
cipitates average a value equivalent to that of
well over 9oo ml fresh net plasma, with a standard
deviation of about r5o ml.
The Factor VIII: flbrinogen ratio in cryopre-
cipitate is the same as that in fresh plasma but the
concentration of other proteins is low so that, on
a protein basis, Factor VIII is about 13 times
more concentrated in comparison with fresh
plasma. With the procedure we used, the con-
centration on a volume basis is about 6 times, but
can easily be increased to ro times. This means
that neither the protein concentration nor the
volume of cryoprecipitate is incompatible with
optimal substitution therapy. This cannot be
maintained quite so categorically with regard to
fraction I according to ConN (two-donor flbri-
nogen) or fraction I-O according to Bt-ol,rsAcrr0.
in which the Factor VIII: flbrinogen ratio is often
considerably smaller than that in cryoprecipitate.
The Factor VIII contained in cryoprecipitate
showed a normal behaviour in vivo: recovery is
virtually complete (Table II), the rate of clearance
from the blood after transfusion in patients with
severe haemophilia A is normal (half-life in the
slow phase is r4 hours; Fig. z), and the haemo-
static effect is excellent. The haemostatic effect
was satisfactory not only in the patients described
in this paper but also in three other cases that we
observed recently. One was a case of severe
haemophilia in which 7o cryoprecipitates were
given within a week in the course of the treatment
of a haematoma of the intestinal wall with ileus.
The second was a little boy suffering from mild
haemophilia A who received 65 cryoprecipitates
and the third was a case of female haemophilia
in which a total of 9r cryoprecipitates were given
in an attempt to ensure post-tonsillectomy wound
healing.
The stability of Factor VIII in cryoprecipitate
at -25"C appears to be satisfactory. There are no
indications of diminution of the activity after a
few month's storage at this temperature. But
further pertinent investigation is required.
No side efects have been observed in the course
of and after transfusions which have so far to-
talled over 65o cryoprecipitates in 13 different
patients. No haemolytic transfusion reaction
need be expected because blood group compati-
bility is taken into account. Flowever, even for
patients of blood groups B and AB who receive
cryoprecipitate from blood group O donors, the
risk of haemolytic reactions is exceedingly small
because the concentrations of incomplete anti-
bociies and haemolysins are so low as to be beyond
the reach of conventional measuring techniques.
The one instance of hepatitis occurred in a man
with severe haemophilia A rvho had hardly
received any transfusions in the Fast and had not
been given y-globulin prophylactically. In terms
of frequency of transfusions, this patient could be
compared with a mild haemophiliac, who receives
only sporadic transfusions and as a rule has not
(yet) had transfusion hepatitis. In the event of
intensive substitution therapy it is therefore
advisable to resort to 1-globulin prophylaxis for
this groupll'zl, the first dose to be given intra-
muscularly during substitution, and the second
dose subcutaneously 4 weeks after the last infu-
sion. A reduction of the hepatitis risk can be
ensured in a different (and perhaps rnore ade-
quate) way by producing cryoprecipitate from a
small number of donors with the aid of plasma-
pheresis2l.
Cryoprecipitate is inexpensive because the pro-
duction of this Factor VIII preparation is consi-
derably less complicated than any other proce-
dure of puriflcation so far used (a laboratory
technician who has the disposal of a single centri-
fuge for centrifuging the double bags can produce
as many as 40-60 cryoprecipitates per week with-
out difficulty, including the collection of blood
and the preparation ofpreserved blood). Further-
more, after isolation of the cryoprecipitate, the
remainder of the blood retains its usefulness for
nearly all indications (over 5o pct flbrinogen
remains in the plasma, and the Factor VIII con-
centration of the preserved blood is rarely of
importance for the recipient).
Partly on the basis of previous studies?,8 the
following can be stated about the amount of
cryoprecipitate required for adequate substitution:
After administering a booster dose at the start of
transfusion treatment and subsequent continuous
infusion of cryoprecipitate, it will take about two
days before the Factor VIII distribution in the
intravascular space is in balance with that in the
extravascular space. The amount of Factor VIII
administered during these two days can be called
the charging dose, while the subsequent dose may
be described as maintenance dose. The following
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hypothetical case nlay serve as an example. In an
adult patient with severe haemophilia A whose
intravascular plasma volume amounts to 2.5 I,
the charging dose will be started by rapid admini-
stration (zo-3o minutes) of r5 pooled cryoprecipi-
tates, which ensures a blood concentration of
-\4o-7o pct (r5 cryoprecipitates contain an amount
of Factor VIII equivalent to rooo-r7oo ml net
fresh plasma). During the first two days after the
starting dose, a constant drip infusion of the
equivalent of t75o-275o ml net fresh plasma daily
G.e. z5 cryoprecipitates daily) will maintain the
Factor VIII concentration in the plasma at 4o-6o
pct. The maintenance dosage can be started on
the third day of substitution therapy once a con-
stant blood level is ensured because the amount
administered balances degradation. With a con-
stant drip infusion, the daily amount H of Factor
VIII to be transfused - in equivalents of ml freshly
drawn normal net plasma - can be approximated
as follows?:
H : t7 x intravascular plasma space (in liters)
x desired blood level (pct)
The constant 17 is derived from
o.693xz4x  r .4xrooo
14 X IOO
in which o.693 represents the natural log. of z, z4the
duration of infusion in hours, r.4 the correction for
the initial rapid disappearance of Factor VIII (half-life
4 hours), and 14 the biological half-life of Factor
VIII in hours.
In the haemophiliac with a plasma volume of 2.5 I
presented as an example, therefore, maintenance
of a 4o pct concentration during the 3rd and 4th
day of substitution requires the equivalent of
some rToo ml net fresh plasma (averaging almost
zo cryoprecipitates daily). During the subsequent
ro days, the equivalent of 1275 ml (averaging
almost 15 cryoprecipitates daily) will suffice to
maintain an average concentration of 3o pct,
with minimum values not below z5 pct. The total
number of cryoprecipitates required for substitu-
tion will in this case be about z5o; in terms of
Factor VIII concentrations in plasma this gua-
rantees a safe margin especially during the first
four days of substitution. In actual practice it may
of course be necessary to modify the dosage, de-
pendent on the results of Factor VIII assays in
the patient's blood. These assays should be car-
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ried out at least twice a day during substitution
therapy. Adjustment of the dosage is most likely
to be necessary in the event of an increased cata-
bolism as occurs in complicated wound healing
or in the presence of other disturbances in the
postoperative or posttraumatic course. ln these
cases the Factor VIII requirement may well in-
crease to twice the normal dosage8 because the
Factor VIII consumption is twice as high. Before
starting planned substitution therapy, therefore,
it must be ensured that the number of cryopre-
cipitates available amounts to twice the number
calculated for a normal catabolism; in the above
theoretical example this number of cryoprecipi-
tates would be about 5oo.
From the considerations given above a general
dosage scheme can be derived for an adult patient,
assuming a mean yield of 45 pct Factor VIII per
cryoprecipitate, and no in vitro deterioration of
Factor VIII during continuous drip infusion
(Table IV). In the case of children the dosage
scheme is essentially the same but owing to the
smaller number of cryoprecipitates administered
daily the large variation in Factor VIII yield per
cryoprecipitate already mentioned will lead to less
predictable plasma levels for Factor VIII.
Nevertheless, the values found in the case of
the boy with mild haemophilia A who underwent
a herniotomy, show that our estimate of the
number of cryoprecipitates required for adequate
substitution therapy is not far from the actual
amount administered. In this boy with an esti-
T,qnrB lV: GnNlnal DosAGE scHEME FoR ADMTNTsTRA-
TION OF CRYOPRECIPITATE
cryoprecipitates per kg body weight
Initial dose*
(rapid infusion)
First 2 days
3rd and 4th day
Subsequent
10 days
o.24
0.40-0.80 daily
0.30-0.60 daily
0.23-0.46 daily
xOf course a test dose wili be given a few hours (or a
day) before a planned surgical intervention in order to
rule out a circulating anti-Factor VIII anticoagulant.
For this purpose the adult patient may be given ro
pooled cryoprecipitates; the blood Factor VIII con-
centration is then determined ro minutes and 7o
minutes after this administration.
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mated plasma volume of o.88 l, daily administra-
tion of an amount of Factor VIII which averaged
the equivalent of 8oo ml net fresh plasma, ensured
an average Factor VIII concentration roughly
estimated as 6o pct (Fig. +). As calculated with
the aid of the above equation, the theoretical
prediction (assuming continuous infusion, the
same Factor VIII turnove_r-as in adults and an
unchanged physiological Factor VIII production
of ro pct) would have been:
8oo
Io pct + ^^ pct - 63.5 pcr
o . u u x t 7
Many further observations on substitution with
continuous drip infusion will of course be re-
quired to verify the correctness of the dosage
scheme given above.
The fibrinogen concentration to be expected
during substitution is dependent on the physiolo-
gical flbrinogen production and the amount of
fibrinogen transfused. In the event of a compli-
cated postoperative or posttraumatic course, the
physiological production can of itself result in a
blood concentration exceeding rooo mg/roo ml.
To this, the transfused fibrinogen adds about
rooo mg/roo ml, assuming that the distribution
space for fibrinogen is the same as that for Factor
VIII, that the biological half-life of fibrinogen is
roo hours and that, after the first 4 days, the
amount of cryoprecipitate given does not exceed
that required to rnaintain a Factor VIII concen-
tration of 3o pct. The correctness of these as-
sumptions is supported by the case of the boy,
in whom a maximum fibrinogen concentration
of r5oo mg/roo ml was observed during an
uneventful postoperative course (Fig. 4). Since
a blood fibrinogen concentration of zooo-3ooo
mg/roo ml has no untoward effects, fibrinogen
will not be a limiting factor in substitution
therapy with cryoprecipitate.
Finally it may be pointed out that, especially
with a view to reducing the hepatitis risk, attempt
must be made (apart from a plasmapheresis pro-
grammelto raise the Factor VIII yield per donor.
Moreover, a study should be made of the stability
of cryoprecipitates, both in deep-frozen dissolved
form and when lyophilized. It may be possible
also to use cryoprecipitate as the starting material
for the preparation of a highly concentrated
human Factor VIII product.
Surrarralny AND coNCLUsIoNs
An evaluation was made of the Factor VIII acti-
vity of some 65o cryoprecipitates.
In vitro, pools of ro cryoprecipitates have a
Factor VIII activity which equals that of 9oo(* t3o) ml freshly drawn normal plasma. The
average yield of Factor VIII is nearly 45 pct; the
Factor VIII: flbrinogen ratio remains unchanged.
Considered on a protein basis, Factor VIII in
cryoprecipitate can be described as about r3-fold
purified.
In vivo, the recovery of Factor VIII following
a single transfusion of ro cryoprecipitates does
not differ from roo pct, regardless of the severity
of the transfusee's haemophilia. During the fust
24 hours after transfusion, Factor VIII disappears
from the blood much more rapidly than during
the next 24 hours. The initial rapid disappeararrce
can be regarded as due to a combination of equili-
bration between the intravascular and the extra-
vascular space (halfJife 4 hours) and biological
decay. The slower degradation during the second
24 hours may be regarded as due merely to biol-
ogical decay (half-life r4 hours). The haemostatic
effect, observed in a case of herniotomy and in
one of tonsillectomy, was excellent.
Our observations indicate that a minimum re-
quirement of z5o cryoprecipitates will be needed
if major surgery is to be covered safely in an adult
with severe haemophilia. The requirement in
mild haemophilia is less because the rate of (de-
fective) Factor VIII production does not seem to
be altered by cryoprecipitate infusions.
Apart from one case of hepatitis, no untoward
reactions were observed. Neither fibrinogen nor
iso-antibodies appear to be limiting factors for
this transfusion therapy.
First-rate quality, outstanding simplicity of
preparation and blood bank economy are the
reasons why cryoprecipitates are now being pro-
duced on a routine scale in our hospital.
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